Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 20, 2020

Verrica Pharmaceuticals announces presentation of positive data from new pooled analysis of phase 3 CAMP trials of VP-102

Verrica Pharmaceuticals announced the presentation of positive data from a post-hoc pooled analysis of the pivotal Phase 3 CAMP trials evaluating the safety and efficacy of VP-102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum (molluscum).

Verrica Pharmaceuticals announces presentation of positive data from new pooled analysis of phase 3 CAMP trials of VP-102